161 related articles for article (PubMed ID: 10964025)
1. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies for uterine leiomyoma: the role of hormonal modulation.
Cook JD; Walker CL
Semin Reprod Med; 2004 May; 22(2):105-11. PubMed ID: 15164305
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
7. Does raloxifene inhibit the growth of uterine fibroids?
Palomba S; Zullo F; Orio F; Lombardi G
Fertil Steril; 2004 Jun; 81(6):1719-20; author reply 1720-1. PubMed ID: 15193512
[No Abstract] [Full Text] [Related]
8. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
9. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.
Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C
Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178
[TBL] [Abstract][Full Text] [Related]
10. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
13. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo.
Howe SR; Gottardis MM; Everitt JI; Walker C
Endocrinology; 1995 Nov; 136(11):4996-5003. PubMed ID: 7588234
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
15. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women.
Walker CL; Hunter D; Everitt JI
Genes Chromosomes Cancer; 2003 Dec; 38(4):349-56. PubMed ID: 14566855
[TBL] [Abstract][Full Text] [Related]
16. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
[TBL] [Abstract][Full Text] [Related]
17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
18. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids.
Salama SA; Nasr AB; Dubey RK; Al-Hendy A
J Soc Gynecol Investig; 2006 Dec; 13(8):542-50. PubMed ID: 17088081
[TBL] [Abstract][Full Text] [Related]
19. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Terán Dávila J; Teppa Garrán AD
Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice.
Al-Hendy A; Lee EJ; Wang HQ; Copland JA
Am J Obstet Gynecol; 2004 Nov; 191(5):1621-31. PubMed ID: 15547533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]